Toxicological Evaluation and In Silico Identification of Acetylcholinesterase Inhibitors in a Commercial Polyherbal Formulation (KWAPF01)

Table 2

Behavioural and morphological changes following oral dosing with KWAPF01.

Dose (mg/kg)	Observations
0	Normal behavioural repertoire
1000	No changes in motility, and mild piloerection
1500	Reduced motility, tremor, and mild piloerection
2000	Reduced motility, tremor, and piloerection
2500	Marked reduction in motility, tremor, and piloerection
3000	Marked reduction in motility, tremor, and piloerection